video img

Videos & Podcasts

Clinicians discuss managing IBS-D and how they connect with patients who live with IBS-D

Access insights >
resources img

Resource Center

Clinical tools and resources to aid in discussions with patients, IBS-D diagnosis, and treatment

View resources >
calender img

Events Calendar

Upcoming live and virtual events with content that may be relevant for your practice

See events >

Popular on GastroHub IBS-D

Direct access to resources for managing IBS-D.

Making a Positive IBS-D Diagnosis Video

My Approach: Making a Positive IBS-D Diagnosis

Mackenzie McArthur, PA-C, demonstrates how she uses a guideline-based approach and clinical criteria to make a positive diagnosis of IBS-D.

Watch video >
IBS-D Patient Discussion Guide

IBS-D Patient Discussion Guide

Encourages patients to have a discussion with their healthcare provider about the symptoms they experience. Have your patients complete the quick discussion questions to aid in discussions and symptom-based diagnosis of IBS-D.

Download PDF >
XIFAXAN IBS-D Treatment Dosing Guide for Nurse Practitioners (NPs) and Physician Assistants (PAs)

XIFAXAN Dosing for IBS-D

Review the recommended dosing for IBS-D in adults and for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. Refer to this dual-indication card for XIFAXAN dosing – includes the ICD-10 code* for IBS-D.

Download PDF >
XIFAXAN IBS-D Treatment Patient Brochure for Nurse Practitioners (NPs) and Physician Assistants (PAs)

XIFAXAN Patient Brochure

Informational brochure for patients that provides an overview of IBS-D and treatment with XIFAXAN, including how XIFAXAN works, how to take XIFAXAN, efficacy, safety, and most common side effects. Provide this brochure to patients to help them understand treatment with XIFAXAN.

Download PDF >
XIFAXAN Treatment Savings Card

XIFAXAN Savings Card

Most eligible† patients with commercial insurance and coverage for XIFAXAN may pay as little as $0 for their XIFAXAN prescription. Maximum benefits and other restrictions apply.

Get savings card >
Visit Resource Center

*The ICD-10 Codes and all other patient-access-related information are provided for informational purposes only. It is the treating physician’s responsibility to determine the proper diagnosis, treatment and applicable ICD-10 Code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

†Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.

Don’t miss new resources!

Sign up to stay informed of updates to GastroHub.

Sign Up Now
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    • HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

SEE MORE

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.